Tangshenkang to prevent and treat diabetic nephropathy

Based on TGFß1/Smads Pathway, To Explore the Mechanism of Regulation of DN Lipid Metabolism by Gualouqvmaitang

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025409

Enrollment

Unknown

Registered

2019-08-26

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

therapy group:Tangshenkang + ACEI class of drugs (benazepril)

Control group:ACEI (benazepril) + ARB drug (valsartan)

Control group:ACEI class of drugs(benazepri)

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. TCM syndrome differentiation is a pancreatic syndrome of yang deficiency, and the clinical stage does not exceed phase III (including stage III). 2. The course of diabetes patients is 5 years or more; 3. Blood pressure is normal or slightly elevated.

Exclusion criteria

Exclusion criteria: Diabetic patients with more proteinuria (24-hour urinary protein >0.5g), or urinary albumin excretion rate >200µg/min (radioimmunoassay).

Design outcomes

Primary

Measure	Time frame
24hUPro;UMA;Fasting blood glucose;serum creatinine (Scr);urea nitrogen (BUN);triglyceride;Glycated hemoglobin;Vascular endothelial growth factor;Connective tissue growth factor;Thromboxane(TXB2);Serum hypersensitive C-reactive protein(hs-CRP);	—

Countries

China

Contacts

Public ContactZhu Hong

Yangzhou University Medicine college

zhuhong@yzu.edu.cn+86 13852713358

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026